驱动基因少见突变晚期非小细胞肺癌的研究进展

Progress of driving gene rare mutations in advanced non-small cell lung cancer

近年来随着晚期非小细胞肺癌(NSCLC)驱动基因少见突变研究的持续进展,以及分子生物学技术的不断发展,分子检测和个体化治疗成为晚期NSCLC患者的标准诊治策略,探寻NSCLC的驱动基因成为研究热点。分子检测技术的发展、新驱动基因的发现以及新药的不断涌现,都使得NSCLC少见靶点突变的治疗越来越精准化。文章检索并筛选了近年来国内外发表的晚期NSCLC患者驱动基因少见突变相关的文献,并对这方面的研究进展进行分析和整理,期望能为NSCLC患者制定更为合理精准的治疗方案,为NSCLC治疗的临床研究指引方向。

In recent years,with the continuous development of driving gene rare mutations of advanced non-small cell lung cancer(NSCLC)patients and molecular biology technology,molecular detection and individualized therapy have become standard diagnosis and treatment strategies for patients with advanced NSCLC.The driving gene of NSCLC has become a research focus.The development of molecular detection technology,the discovery of new driving gene and the continuous emergence of new drugs have made the treatment of rare target mutations in NSCLC increasingly precise.This article retrieves and screens out the documents published in recent years which are related to driving gene rare mutations in patients with advanced NSCLC,and analyzes the relevant research progress.It is hoped that more reasonable and accurate treatment plans can be formulated for NSCLC patients to guide the clinical research of NSCLC treatment.